Misoprostol Protects Mice Against Severe Clostridium Difficile Infection and Promotes Recovery of the Gut Microbiota After Antibiotic Perturbation

Overview

Journal Anaerobe

Date 2019 Jun 21

PMID 31220605

Citations 11

Authors

Joseph P Zackular

Leslie Kirk

Bruno C Trindade

Eric P Skaar

David M Aronoff

Affiliations

Soon will be listed here.

Abstract

Clostridium difficile infection (CDI) is one of the most common nosocomial infections worldwide and an urgent public health threat. Epidemiological and experimental studies have demonstrated an association between nonsteroidal anti-inflammatory drug (NSAID) exposure and enhanced susceptibility to, and severity of, CDI. NSAIDs target cyclooxygenase enzymes and inhibit the production of prostaglandins (PGs), but the therapeutic potential of exogenous introduction of PGs for the treatment of CDI has not been explored. In this study, we report that treatment with the FDA-approved stable PGE analogue, misoprostol, protects mice against C. difficile-associated mortality, intestinal pathology, and CDI-mediated intestinal permeability. Furthermore, we report that the effect of misoprostol on the gastrointestinal tract contributes to increased recovery of the gut microbiota following antibiotic perturbation. Together, these data implicate PGs as an important host-factor associated with recovery to C. difficile-associated disease and demonstrate the potential for misoprostol in the treatment of CDI. Further studies to explore the safety and efficacy of misoprostol treatment of CDI in humans is needed.

Citing Articles

New treatment approaches for infections: alternatives to antibiotics and fecal microbiota transplantation.

Bratkovic T, Zahirovic A, Bizjak M, Rupnik M, Strukelj B, Berlec A Gut Microbes. 2024; 16(1):2337312.

PMID: 38591915 PMC: 11005816. DOI: 10.1080/19490976.2024.2337312.

Nonsteroidal anti-inflammatory drugs sensitize epithelial cells to toxin-mediated mitochondrial damage.

Soto Ocana J, Bayard N, Hart J, Thomas A, Furth E, Lacy D Sci Adv. 2023; 9(29):eadh5552.

PMID: 37467340 PMC: 10355836. DOI: 10.1126/sciadv.adh5552.

The Urgent Threat of Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects.

Alshrari A, Hudu S, Elmigdadi F, Imran M Biomedicines. 2023; 11(2).

PMID: 36830964 PMC: 9953237. DOI: 10.3390/biomedicines11020426.

Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent Clostridioides difficile during COVID-19.

Lavieri R, Dubberke E, McGill S, Bartelt L, Smith S, Pandur B Anaerobe. 2023; 80:102699.

PMID: 36702174 PMC: 10793995. DOI: 10.1016/j.anaerobe.2023.102699.

Pain killers: the interplay between nonsteroidal anti-inflammatory drugs and Clostridioides difficile infection.

Soto Ocana J, Bayard N, Zackular J Curr Opin Microbiol. 2021; 65:167-174.

PMID: 34894543 PMC: 9058983. DOI: 10.1016/j.mib.2021.11.011.

References

Sasaki S, Hirata I, Maemura K, Hamamoto N, Murano M, Toshina K . Prostaglandin E2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines. Scand J Immunol. 2000; 51(1):23-8. DOI: 10.1046/j.1365-3083.2000.00623.x. View

Onizuka Y, Murase K, Furusu H, Isomoto H, Mizuta Y, Takeshima F . Effect of intrarectal prostaglandin E2 analogue (enprostil) on trinitrobenzenesulphonic acid-induced colitis in rats. J Int Med Res. 2000; 28(1):28-35. DOI: 10.1177/147323000002800105. View

Martin A . Phylogenetic approaches for describing and comparing the diversity of microbial communities. Appl Environ Microbiol. 2002; 68(8):3673-82. PMC: 124012. DOI: 10.1128/AEM.68.8.3673-3682.2002. View

Walt R . Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med. 1992; 327(22):1575-80. DOI: 10.1056/NEJM199211263272207. View

Torsher K, Empey L, Fedorak R . Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing. Prostaglandins Leukot Essent Fatty Acids. 1992; 45(4):275-81. DOI: 10.1016/0952-3278(92)90083-u. View

Yamada T, Fujimoto K, Tso P, Fujimoto T, Gaginella T, Grisham M . Misoprostol accelerates colonic mucosal repair in acetic acid-induced colitis. J Pharmacol Exp Ther. 1992; 260(1):313-8. View

Wang Q, Garrity G, Tiedje J, Cole J . Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007; 73(16):5261-7. PMC: 1950982. DOI: 10.1128/AEM.00062-07. View

Pruesse E, Quast C, Knittel K, Fuchs B, Ludwig W, Peplies J . SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res. 2007; 35(21):7188-96. PMC: 2175337. DOI: 10.1093/nar/gkm864. View

Cutler D, Edwards Jr T, Beard K, Cutler A, Hess K, Gibson J . Random forests for classification in ecology. Ecology. 2007; 88(11):2783-92. DOI: 10.1890/07-0539.1. View

10.

Yamada T, Specian R, Granger D, Gaginella T, Grisham M . Misoprostol attenuates acetic acid-induced increases in mucosal permeability and inflammation: role of blood flow. Am J Physiol. 1991; 261(2 Pt 1):G332-9. DOI: 10.1152/ajpgi.1991.261.2.G332. View

11.

Schloss P, Westcott S, Ryabin T, Hall J, Hartmann M, Hollister E . Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009; 75(23):7537-41. PMC: 2786419. DOI: 10.1128/AEM.01541-09. View

12.

Fedorak R, Empey L, MacArthur C, Jewell L . Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology. 1990; 98(3):615-25. DOI: 10.1016/0016-5085(90)90280-e. View

13.

Edgar R, Haas B, Clemente J, Quince C, Knight R . UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 2011; 27(16):2194-200. PMC: 3150044. DOI: 10.1093/bioinformatics/btr381. View

14.

Carter G, Douce G, Govind R, Howarth P, Mackin K, Spencer J . The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 2011; 7(10):e1002317. PMC: 3192846. DOI: 10.1371/journal.ppat.1002317. View

15.

Rogers M, Greene M, Saint S, Chenoweth C, Malani P, Trivedi I . Higher rates of Clostridium difficile infection among smokers. PLoS One. 2012; 7(7):e42091. PMC: 3407081. DOI: 10.1371/journal.pone.0042091. View

16.

Rogers M, Greene M, Young V, Saint S, Langa K, Kao J . Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med. 2013; 11:121. PMC: 3651296. DOI: 10.1186/1741-7015-11-121. View

17.

Theriot C, Koenigsknecht M, Carlson Jr P, Hatton G, Nelson A, Li B . Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014; 5:3114. PMC: 3950275. DOI: 10.1038/ncomms4114. View

18.

Rogers M, Micic D, Blumberg N, Young V, Aronoff D . Storage duration of red blood cell transfusion and Clostridium difficile infection: a within person comparison. PLoS One. 2014; 9(2):e89332. PMC: 3931729. DOI: 10.1371/journal.pone.0089332. View

19.

Fowler T, Durham C, Planton J, Edlund B . Use of nonsteroidal anti-inflammatory drugs in the older adult. J Am Assoc Nurse Pract. 2014; 26(8):414-423. DOI: 10.1002/2327-6924.12139. View

20.

Montrose D, Nakanishi M, Murphy R, Zarini S, McAleer J, Vella A . The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat. 2014; 116-117:26-36. PMC: 4385488. DOI: 10.1016/j.prostaglandins.2014.10.002. View